Miragen

Privately held Miragen will pick up Signal's Nasdaq listing, and the combined company is scheduled to begin trading today.

The combined company will be focused on Miragen's microRNA therapeutics programs, following the divestiture of Signal's molecular diagnostic assets.

Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.

NEW YORK (GenomeWeb) – Miragen Therapeutics this week announced that its research and development collaboration with France's Servier has been extended by two years to October 2016.

Voyager Therapeutics, a startup developing adeno-associated viral vector therapies, including RNAi-based ones, for central nervous system disorders, has named Dinah Sah as its senior vice president of neuroscience.

This article has been updated to clarify Monsanto's relationship with Miragen and miR-168a's effect on low-density lipoprotein.

MiRagen Therapeutics has named Aimee Jackson as its director of target development and Christopher Morl as its chief business officer.

MiRagen Therapeutics this week said it has achieved the first milestone in its partnership with Les Laboratoires Servier, with the French company selecting a third target for microRNA drug development.
The move triggered an undisclosed milestone payment to MiRagen.

Miragen Therapeutics said this week that it has taken an exclusive license to intellectual property held by the University of Glasgow that is related to the use of microRNA-145 in the treatment of pulmonary arterial hypertension.
Terms of the deal were not disclosed.

Santaris Pharma and Miragen Therapeutics this week announced that they have expanded their ongoing microRNA therapeutics partnership to include six additional targets.

Pages

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.